Amplia Therapeutics Says Initiation Activities for US Pancreatic Cancer Trial Underway

MT Newswires Live
04-09

Amplia Therapeutics (ASX:ATX) said initiation activities for its pancreatic cancer trial in the US have started, focusing on the combination of the company's focal adhesion kinase inhibitor narmafotinib with chemotherapy Folfirinox for advanced pancreatic cancer patients, according to a Wednesday filing with the Australian bourse.

The company partnered with a contract research organization to manage clinical trial activities in the US, the filing said.

The trial will be run under the investigational new drug application for narmafotinib which was cleared by the US Food and Drug Administration, per the filing.

Shares rose nearly 2% in recent trade Wednesday.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10